Ethicon Opens Up To Chronic Sinusitis Market With $785 Mil. Acclarent Buy
This article was originally published in The Gray Sheet
Johnson & Johnson/Ethicon will use its $785 million acquisition of Acclarent, developer of the Balloon Sinuplasty system for chronic sinusitis, as a platform for growth in the ear, nose and throat business
You may also be interested in...
The Blue Cross Blue Shield Technology Evaluation Center considered balloon ostial dilation for the treatment for chronic rhinosinusitis; multianalyte testing for evaluation of adnexal masses; and nucleic acid sequencing-based testing of maternal plasma for fetal aneuploidy.
Firm unveils a range of new products for minimally invasive treatment of ear, nose and throat conditions Sept. 10 at the American Academy of Otolaryngology-Head and Neck Surgery annual conference in Washington, D.C.
Ethicon sales rose 8.2% to $1.13 billion in the second quarter, driven by sutures, biosurgicals and Mentor aesthetic devices, Johnson & Johnson reported July 20. The acquisition of Acclarent also contributed to growth, the firm noted. J&J bought the Balloon Sinuplasty developer for $785 million in December (1"The Gray Sheet" Dec. 21, 2009). Advanced sterilization and Harmonic ultrasonic devices helped grow Ethicon Endo-Surgery revenues 6.6% to $1.2 billion. The Cordis division continued to struggle, with sales dropping 2.8% to $655 million. Medical devices and diagnostics sales of $6.1 billion were up 3.5% overall